December's 5 NMEs Filings: Ranexa, Certican, Memantine, 2 HIV Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
At least five new molecular entities reached FDA in the final month of 2002, bringing the total number of NME submissions for calendar year 2002 to 19.
You may also be interested in...
New Drug Approvals In 2003 Could Include Four HIV Agents
FDA’s new molecular entity approval totals for 2003 could feature as many as four novel HIV agents.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011